Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Open Access
- 1 August 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 11 (4), 348-356
- https://doi.org/10.1215/15228517-2009-001
Abstract
The O6-methylguanine-DNA methyltransferase gene (MGMT) is methylated in several cancers, including gliomas. However, the functional role of cysteine-phosphate-guanine (CpG) island (CGI) methylation in MGMT silencing is still controversial. The aim of this study was to investigate whether MGMT CGI methylation correlates inversely with RNA expression of MGMT in glioblastomas and to determine the CpG region whose methylation best reflects the level of expression. The methylation level of CpG sites that are potentially related to expression was investigated in 54 glioblastomas by pyrosequencing, a highly quantitative method, and analyzed with respect to their MGMT mRNA expression status. Three groups of patients were identified according to the methylation pattern of all 52 analyzed CpG sites. Overall, an 85% rate of concordance was observed between methylation and expression (p < 0.0001). When analyzing each CpG separately, six CpG sites were highly correlated with expression (p < 0.0001), and two CpG regions could be used as surrogate markers for RNA expression in 81.5% of the patients. This study indicates that there is good statistical agreement between MGMT methylation and expression, and that some CpG regions better reflect MGMT expression than do others. However, if transcriptional repression is the key mechanism in explaining the higher chemosensitivity of MGMT-methylated tumors, a substantial rate of discordance should lead clinicians to be cautious when deciding on a therapeutic strategy based on MGMT methylation status alone.This publication has 34 references indexed in Scilit:
- Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*Brain Pathology, 2008
- DNA methylation analysis by pyrosequencingNature Protocols, 2007
- Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell lineMolecular Cancer Therapeutics, 2006
- The Essential Role of Histone H3 Lys9 Di-Methylation and MeCP2 Binding in MGMT Silencing with Poor DNA Methylation of the Promoter CpG IslandThe Journal of Biochemistry, 2005
- Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumorsInternational Journal of Cancer, 2004
- Primary brain tumours in adultsThe Lancet, 2003
- DNA methylation and gene silencing in cancer: which is the guilty party?Oncogene, 2002
- Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormoneOncogene, 1999
- Understanding and manipulating O6-methylguanine-DNA methyltransferase expressionPharmacology & Therapeutics, 1997
- Methylation of CpG Island Transcription Factor Binding Sites Is Unnecessary for Aberrant Silencing of the Human MGMT GeneOnline Journal of Public Health Informatics, 1996